Clinical Study of ICP-192 in Solid Tumors Patients

Solid Tumor Clinical Trial

Official title:

A Phase I/IIa, Multicenter, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics of ICP-192 in Patients With Advanced Solid Malignancies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03758664
• Other study ID #: ICP-CL-00301
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: December 19, 2018
• Est. completion date: December 31, 2024

Study information

• Verified date: June 2022
• Source: Beijing InnoCare Pharma Tech Co., Ltd.
• Contact: Jin Li, PhD
• Phone: 8621-38804518
• Email: lijin[@]csco.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Open-label, non-randomized, Phase I/IIa, dose-escalating, dose-extension, first-in-man study.

Description:

The study consisted of a screening period, a treatment period with 21 days of repeated treatment per cycle (duration treatment with ICP-192), and a follow-up period (28 days after last dose). The recruited patients receive a single dose on day 1, then after a 3-day washout period, repeated dosing will be followed. The starting dose is 2 mg, QD, and dose escalation will follow accelerated titration and modified 3+3 dose-finding schema. The dose-limiting toxicity (DLT) assessment period consisted of Cycle 0 (single dose and washout period) and Cycle 1 (21-day cycle).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 56
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. An unresectable or metastatic advanced malignant solid tumor confirmed by histopathology that has failed to respond to known treatment or has recurred;Subjects who progress under standard treatment, are intolerant to standard treatment, or do not have standard treatment (dose escalation phase)

2. Tissue or cell pathology confirmed unresectable, recurrent or metastatic (AJCC version 8 TNM staging IV (2017), biliary tract malignant tumor, or intolerance to first-line chemotherapy failure (twice (defined as reduction still cannot tolerate) first-line chemotherapy, neoadjuvant/progress/adjuvant chemotherapy after 6 months recurrence can be selected (dose extension stage); - At least one evaluable disease according to RECIST1.1

3. FGFR2 translocation/fusion has been reported or FGFR2 translocation/fusion has been detected in central laboratory (dose extension phase);

4. Age =18 and =75

5. There is at least one evaluable lesion according to RECIST1.1 criteria

6. ECOG strength score is 0-1 (dose escalation stage), and ECOG strength score is 0-2 (dose expansion stage).

7. The expected survival time is more than 3 months

8. The organ function level must meet the following requirements (subject to the upper limit of normal value in the clinical trial center):

A) bone marrow: absolute count of neutrophils (ANC)=1.5*109/L (1500/mm3), platelet =75*109/L, hemoglobin =9g/dL; B) coagulation function: international standardized ratio of prothrombin time and partial thrombin time <1.5 times the upper limit of normal value; C) liver: serum bilirubin =1.5 times the upper limit of normal value (tumor involvement in the liver =2.5 times the upper limit of normal value), aspartic aminotransferase (AST) and alanine aminotransferase (ALT)=3 times the upper limit of normal value (AST and ALT=5 times the upper limit of normal value in the case of liver metastasis); D) serum creatinine =1.5 times the upper limit of normal value, or creatinine clearance =70mL/min (calculated according to the Cockroft-gult formula).

9. Volunteer to enroll and sign informed consent to follow the treatment protocol and visit plan.

Exclusion Criteria:

• Previous treatment with FGFR small molecule inhibitors or antibody drugs.

• Anti-cancer therapy, such as chemotherapy (except for oral fluorouracil), immunotherapy, hormonal, targeted therapy, or investigational agents within four weeks of the first dose of ICP-192, oral fluorouracil agents within two weeks of the first dose of ICP-192.

• Major surgery within 6 weeks of the first dose of ICP-192.

• Blood phosphate persistently above ULN with intervene therapy within two weeks of the first dose of ICP-192.

• Significant GI disorder(s) that could interfere with the absorption, metabolism, or excretion of ICP-192.

• Central nervous system (CNS) metastasis

• Current clinically significant cardiovascular disease including:

• Any class 3 or 4 cardiac disease such as arrhythmia, congestive heart failure or myocardial infarction defined by the New York Heart Association Functional Classification, or left ventricular ejection fraction (LVEF) < 50%, Primary cardiomyopathy, clinical significant QTc prolong history or QTc>470ms (female) QTc>450ms (male)

• Known active bleeding within 2 months of screening or 6 months of bleeding history.

• According to the investigator's judgement, there are evidences of a serious or uncontrollable systemic disease (such as unstable or uncompensated respiratory, liver or kidney disease); or any unstable systemic disease (including active clinically serious infections, uncontrolled hypertension, liver and kidney or metabolic diseases)

• History of interstitial pneumonia, deep vein thrombosis, pulmonary embolism. Stroke or intracranial hemorrhage within 6 months before the first dose of ICP-192.

• History of organ transplantation and allogeneic hematopoietic stem cell transplantation.

• Any corneal or retinal abnormalities that may increase ocular toxicity, including but not limited to:

• History of central serous retinopathy (CSR) or retinal vein occlusion (RVO) disease or has related diseases;

• Active age-related macular degeneration (AMD);

• Diabetic retinopathy with macular edema;

• Uncontrollable glaucoma;

• Keratonosus, such as Keratitis, keratoconjunctivitis, keratopathy, corneal wear, inflammation or ulceration.

• Known active infection with HBV, HCV or HIV or any uncontrolled active systemic infection

• Any toxicities must recover to = Grade 1 from prior anti-cancer therapy (excluding alopecia, nausea and vomiting).

• Lactating or pregnant women, or women who will not use contraception during the study and for 180 days after the last dose of study drug if sexually active and able to bear children.

• Investigators believe that the patients are not eligible for enrollment for the other reasons.

Related Conditions & MeSH terms

• Solid Tumor

Intervention

Drug:
• ICP-192
Drug: ICP-192 Dose levels will be escalated following accelerated titration and modified "3+3" dose escalation scheme,

Locations

Country	Name	City	State
China	The First Bethune Hospital of Jilin University	Changchun	Jilin
China	Hunan cancer hospital & the affiliated cancer hospital of xiangya school of medicine ,central south university	Changsha	Hunan
China	ZhuJiang Hospital of Southern Medical University	Guangzhou	Guangdong
China	Cancer hospital of the university of Chinese academy of sciences	Hangzhou	Zhejiang
China	Shanghai East Hospital	Shanghai	Shanghai
China	The Second Affiliated Hospital of Soochow University	Suzhou	Jiangsu
China	Henan cancer hospital & Affiliated Tumor Hospital of Zhengzhou University	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Beijing InnoCare Pharma Tech Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse events(Phase 1 dose escalation)	Adverse events graded by CTCAE V5.0 as a measurement of the safety and tolerability profile of ICP-192	From the time a signed and dated ICF until 28 days after last dose of study drug
Primary	Objective Response Rate(ORR)(Phase 2a dose expansion)	Objective response based on assessment of confirmed Complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST).	At the end of Cycle 4(each cycle is 21 days)
Secondary	Cmax	Single dose PK parameters include the peak plasma concentration (Cmax)	At the end of Cycle 1(each cycle is 21 days)
Secondary	AUC	Area under the plasma concentration vs. time curve (AUC)	At the end of Cycle 1(each cycle is 21 days)
Secondary	Apparent half-life for designated elimination phases (t½)	will be measured and calculated with noncompartmental analysis using WinNonlin	At the end of Cycle 1(each cycle is 21 days)
Secondary	Food effect	ICP-192 concentrations in plasma and urine after dosing in fed and fasted condition	Day 1 - 6 after single dose
Secondary	Objective Response Rate(ORR) (Phase 1 dose escalation)	Objective response based on assessment of confirmed Complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST).	At the end of Cycle 4(each cycle is 21 days)
Secondary	Disease control rate(DCR)	DCR based on assessment of confirmed Complete response (CR), partial response (PR) or stable disease(SD) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST).	At the end of Cycle 4(each cycle is 21 days)
Secondary	Duration of Objective Response (DOR)	Duration of objective response is time interval from the first date that criteria for complete response or partial response are met to the first date of progression of disease	At the end of Cycle 4(each cycle is 21 days)
Secondary	Progression Free Survival (PFS)	Progression free survival is the time period from start of study medication till the disease progression or death, whichever occurs first.	At the end of Cycle 4(each cycle is 21 days)
Secondary	Correlationship between FGFR aberrations with efficacy. (Phase 2a dose expansion)	Correlationship between FGFR mutation/refusion with ORR	At the end of Cycle 4(each cycle is 21 days)